award

PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis

  • Award Number: U01AI170426

  • ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

  • OPDIV: NIH

  • AWARD CLASS: COOPERATIVE AGREEMENT

  • AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

  • PERIOD OF PERFORMANCE START DATE: 05/01/2025

  • PERIOD OF PERFORMANCE END DATE: 07/16/2026